ATRS = solid grow play (in ~2.10) ARGS = very spec. immuno-oncology and HIV play (in at .15)
both have catalysts coming up, ATRS FDA decision on CRL'ed (XYOSTED) and new drug/devices and partner news (Makena, Byetta/generic EpiPen), ARGS phase 3 readout for rocapuldencel t (mrcc) and phase 2 for args-004 (hiv eradication with very mild side effects only)
ARGS = very spec. immuno-oncology and HIV play (in at .15)
both have catalysts coming up, ATRS FDA decision on CRL'ed (XYOSTED) and new drug/devices and partner news (Makena, Byetta/generic EpiPen), ARGS phase 3 readout for rocapuldencel t (mrcc) and phase 2 for args-004 (hiv eradication with very mild side effects only)
#investing